In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion.
To read more, click the link below.
Drug price controls in the US: A roundtable discussion with experts
The United States is the world leader in innovative drug development, supporting patients and health systems globally by advancing the creation of new cures...